In a new note to investors today, an analyst has provided a rating update for the NA sector company, MedReleaf Corp (TSX: LEAF). The company received a Hold rating from Clarus’ analyst Noel Atkinson.
Atkinson has an average return of 127.6% when recommending MedReleaf Corp.
According to TipRanks.com, Atkinson is ranked #118 out of 4829 analysts.
Read also: Sarepta (SRPT): Did You Feel the Ground Shake, Too?
MedReleaf Corp has an analyst consensus of Moderate Buy, with a price target consensus of C$31.25.
The company has a one-year high of C$31.25 and a one-year low of C$7.45. Currently, MedReleaf Corp has an average volume of 645.4K.
MedReleaf Corp. engages in the production and sale of medical cannabis. Its cannabis products include dried, oil, and oil capsules. The company was founded by Neil J. Closner and Eitan Popper on February 28, 2013 and is headquartered in Markham, Canada.
The company’s shares closed on Wednesday at C$28.89, close to its 52-week high of C$31.25.
